ARTA
APTO

A.R.T. Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

A.R.T. Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-150
Closed -$383K – 1130
2019
Q4 		$383K Buy
+150
New +$195K 0.02% 946
2018
Q3 		– Sell
-25
Closed -$45K – 1804
2018
Q2 		$45K Buy
+25
New +$39.9K ﹤0.01% 1340

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

A.R.T. Advisors's APTO Position: Q1 2020 in Review

A.R.T. Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q1 2020, closing a stake of 150 shares — an estimated $383K sold.

A.R.T. Advisors first reported a position in APTO in Q2 2018 and held it in 2 quarters. The position peaked at $383K in Q4 2019. 51 funds tracked by Wall St. Rank hold APTO as of Q1 2020.

  • A.R.T. Advisors reported no remaining Aptose Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 150 Aptose Biosciences, Inc. shares in Q1 2020, an estimated $383K.
  • A.R.T. Advisors first reported a position in Aptose Biosciences, Inc. in Q2 2018 and held it in 2 quarters.
  • A.R.T. Advisors's Aptose Biosciences, Inc. position peaked at $383K in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.